EQUASENS: FY 2022 revenue: +10.88% to €214.07m
Villers-lès-Nancy, 3 February 2023 - 6:00 p.m.
(CET)
PRESS RELEASE
FY 2022 revenue:
+10.88% to €214.07m
-
Like-for-like (incl. PROKOV EDITIONS in Q4), FY 2022
revenue rose 8.82% to €210.09m.
- The Group
confirms the efficiency of its strategy of promoting
interoperability between healthcare professionals and
establishments, with the priorities of structuring the healthcare
offer, improving coordination between healthcare professionals and
exchanging patient data.
- The
Group strengthens its expertise
and leadership position as a healthcare technology solution
provider with the qualification of 7 software products
under 4 categories of
the Ségur
programme.
-
id. by Pharmagest for
pharmacies, DOMILINK HAD
and DOMILINK SSIAD for
home care healthcare professionals,
HOSPILINK for hospitals and specialised
structures, TITAN for nursing
homes, MédiStory 4 for primary
care practitioners and multidisciplinary group
practices, and MEDILINK
for multidisciplinary group practices.
- The French
Digital Healthcare investment programme
(Ségur du Numérique en
Santé) contributed
€7.10m to 2022
revenue.
- Continuing
expansion in Europe in 2023,
after successfully strengthening its positions in the UK
(CAREMEDS) and Germany (I-MEDS), and developing in
other healthcare segments.
In €m |
2021 |
2022 |
Change |
Q1 |
45.27 |
49.36 |
9.03 % |
Q2 |
48.63 |
54.21 |
11.48 % |
Q3 |
44.21 |
50.13 |
13.39 % |
Q4 |
54.95 * |
60.40 |
9.90 % |
Annual revenue |
193.07 |
214.07 ** |
10.88 % |
* Consolidation of PROKOV EDITIONS in Q4
2021** unaudited
****
2022 highlights
As a reminder, as of January 1, 2022:
- the Digital
Communications Business Unit was integrated into the PHARMAGEST
Division;
- the Telemedicine
business is attached to the AXIGATE LINK Division.
These changes are taken into account for N-1 to
facilitate comparison on an identical basis.
- The
PHARMAGEST Division had revenue of €156.30m at 31 December
2022, a 7.62% increase from one year earlier. This Division
accounted for 73.01% of total Equasens Group's revenue for 2022.
- In
France, annual revenue rose 7.65% to €140.77m.
Apart from the Ségur programme qualification
obtained on 14 November 2022 boosting sales of the id. by
Pharmagest solution (a new, profoundly revamped version of the LGPI
suite) in the final weeks of the year (revenue of €2.02m), this
Business Unit’s growth momentum of the first nine months (+7.24%)
remained on track with notable performances from both its software
activities (launch of new offerings such as id.Mobility and
OffiSecure Fibre, the continued rollout of interoperability
solutions) and hardware (support for the deployment of electronic
labels with the Group's equipment financing offering proposed by
its subsidiary HEALTHLEASE, strengthening of technical and training
teams for installations).
- In
Italy, annual revenue rose 9.19% to €10.40m.
This Business Unit continued to roll out its
offering, with both software solutions for pharmacies (new version
of the id. software) and wholesaler-distributors (deployment of the
new version of the Farmaclick ordering platform), and equipment
(sales of hardware and MULTIMEDS manual pill dispensers). To
achieve its development goals, the Group implemented an investment
plan: strengthening sales and customer service teams (technicians
and instructors), opening new branches to be closer to its
customers.
- Annual revenue in
Belgium was down 4.08% to €2.49m (this Business
Unit represents 1.17% of total Group revenue in 2022).
The Belgian pharmacy sector is continuing its
transition to a business model with a greater focus on the
profitability of its structures. While the situation has stabilized
with pharmacy groups through the joint efforts of the Customer
Service and R&D departments, this Business Unit is continuing
to strengthen its position with the independent companies. With the
new id. version and the launch of electronic labels, the sales team
has considerable strengths.
- Annual revenue of
the Digital Communication Business Unit rose
12.64% to €2.63m.
In addition to the well-known pharmaceutical
companies, the Group has also expanded its portfolio with the
addition of smaller companies. This business mix (catalogue
management, communication and/or notification services, statistics)
has enabled the Business Unit to maintain a steady revenue stream.
In 2022, it completed 165 communication campaigns for nearly 80
partners.
- The AXIGATE
LINK Division had revenue of €32.61m at 31 December 2022,
a 15.00% increase from one year earlier. This Division accounted
for 15.23 % of total Equasens Group's revenue for 2022.
All the Division's activities are growing in
their respective markets, boosted by the rollout of the Ségur
programme offerings:
- The Nursing
Home activity (TITAN solution): +17.72% to €16.58m
(including €1.83m from the Ségur programme).
After a pre marketing phase of TITANLINK (a
multilingual, multicountry cloud version of TITAN), the first
deployments were in France (MALTA INFORMATIQUE) and Belgium (MALTA
BELGIUM).
- For the
Hospital-at-Home care sector (DOMILINK HAD and
DOMILINK SSIAD): +6.23% to €5.90m (including €1.08m from the Ségur
programme).
- For
hospitals (HOSPILINK): +2.87% to €4.37m
(including €0.27m from the Ségur programme).
- For the
Healthcare Establishment and Private Practice
sector (MEDILINK): +22.96% to €5.04m (including €0.64m from the
Ségur programme).
Revenue from pandaLAB Pro grew significantly
(+36% to €1.14m). Bolstered by PANDALAB's dual ISO 27001 and HDS
certification, guaranteeing a high level of confidentiality and
security for health data, pandaLAB Pro will intensify its marketing
efforts, with a particular focus on private establishments.
- The
Telemedicine sector: +94.09% to €0.72m (this
Business Unit accounted for 0.33% of total Group revenue in
2022).
Placing this activity within the AXIGATE LINK
Division dedicated to health and social care facilities and
services will help promote and develop the ETPLINK / HDJLINK
solutions (management of therapeutic programmes and day
hospitalisation / outpatient care for these establishments) as well
as CARELIB EHPAD (resident call services, falls detection and
geolocation solutions for nursing homes) within these healthcare
structures.
- The
E-CONNECT Division had revenue of €16.94m at 31 December
2022, up 6.22% from one year earlier. This Division accounted for
7.91% of total Equasens Group's revenue for 2022.
-
e-Connect Business Unit: +5.10%
to €13.45m.
Adopting a second life CSR strategy enabled this
Business Unit to grow despite constraints imposed by supply chain
difficulties for electronic components that were correctly
anticipated. To limit its effects, the Business Unit thus decided
to accelerate its strategy of increasing the diversification of its
manufacturing subcontracting.
- The Frailty
Management sector (NOVIAcare solutions) declined 49.55% to
€0.03m (this Business Unit accounted for 0.01% of total Group
revenue in 2022).
The business development action plan is starting
to produce results and has boosted the marketing of the LIVIAHOME
by NOVIAcare offering by increasing its access to the general
public thanks to its integration into the BOULANGER Marketplace in
particular. In Europe, qualified partners and manufacturers
(including Netherlands, Belgium, Germany) have approved the first
orders of units to be delivered in the first months of 2023.
- The
Compliance Business Unit (which in 2022 combined the
activities of CAREMEDS, MULTIMEDS and I-MEDS): +11.98% to
€3.45m.
The Business Unit maintained its level of
growth. The acquisition of 100% control of these activities will
accelerate the Group's development of these offerings for the
European customers of the Group's Divisions and strengthen its
position in the European markets (particularly in the UK and
Germany).
- The MEDICAL
SOFT Division (which includes the activity of PROKOV
EDITIONS integrated in Q4 2021) had annual revenue of €6.22m
(+106.90% in Q4 2022 from the same period in 2021). This Division
accounted for 2.90 % of total Equasens Group's revenue for
2022.
As the first company
in the market to obtain Ségur certification for its MédiStory 4
medical software on 05/30/2022, PROKOV EDITIONS once again
demonstrated its commercial agility by immediately deploying its
certified offering while maintaining significant R&D efforts to
develop new innovative modules for specialised physicians in
particular.
- The FINTECH
Division had revenue of €2.01m at 31 December 2022, down
18.03% from one year earlier. This Division accounted for
0.94 % of total Equasens Group's revenue for 2022.
Despite a mature
offering and high quality lending partners, this activity continues
to be impacted by unfavourable conditions in the financing market
caused by significant interest rate increases in 2022.
Outlook
In 2022, Equasens Group validated its growth
strategy (organic and external) while the acceptance of its
software solutions for the Ségur programme provided a confirmation
of its technological know-how and expertise. On that basis, the
Group is expecting annual results to be in line with previous
years.
For 2023, after successfully strengthening its
positions in the UK (CAREMEDS) and Germany (I-MEDS), the Group
maintains its goals for expansion in Europe and development in
other areas of healthcare.
Financial calendar
- 2022 annual
results: 24 March 2023 after the close of trading.
- Analysts meeting on the 2022 annual
results: 27 March 2023, 11:30 a.m. - Paris.
About
Equasens Group
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group is
currently bringing together healthcare professionals within a
unique ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment
and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP -
GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker
Code: EQS
For all the latest news on Equasens Group go to
www.equasens.com
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Frédérique SCHMIDTTel. +33 (0)3 83 15 90 67 -
frederique.schmidt@equasens.com
Media Relations:
FIN’EXTENSO - Isabelle APRILE
Tel. +33 (0)6 19
38 61 78 - i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20230203_2022 REVENUE_en_US
Equasens (EU:EQS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equasens (EU:EQS)
Historical Stock Chart
From Jul 2023 to Jul 2024